Lifeward Q1 revenue down 22%, net loss widens to $10.8M; cash improves to $11.4M

Lifeward Ltd.

Revenue $3.9M (down 22% YoY); AlterG sales fell 38% to $2.1M on supply chain timing.
Net loss $10.8M ($6.70/share) vs $4.8M ($5.53/share) in Q1 2025; one-time $4.9M R&D charge.
Unrestricted cash $11.4M at Mar 31, 2026, up from $2.2M at Dec 31, 2025; $6.5M from Oratech.
Operating cash burn improved 33% YoY to $3.7M; ReWalk exoskeleton sales up 11% to $1.6M.
Strategic transaction closed: $10M financing, Oratech acquisition with oral insulin Phase 2 trial.

item 2.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.